✦ LIBER ✦

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, august 1975-December 1980

✍ Scribed by Moe, Peter Johan ;Seip, Martin ;Finne, Per H. ;Kolmannskog, Svein

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 151 KB
Volume: 14
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950140315

No coin nor oath required. For personal study only.

✦ Synopsis

One hundred fifty-three children with ALL were diagnosed in Norway in the period August 1975-December 1980. One hundred ond remission. thirty-two of them received 3 infusions of methotrexate as consolidation therapy combined with methotrexate intrathecally as CNS prophylaxis. Eleven (44%) of the total 25 methotrexate cases with WBC above 50 x 109/L were in CCR after 4 1/2-10 years. Two more cases had discontinued therapy, while in sec-The event-free survival of all diagnosed 32 children in Norway with WBC above 50 x 109/L was 37%. Seven infants below the age of 1 year are included in the 32 cases.

📜 SIMILAR VOLUMES

Methotrexate infusions in poor prognosis

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia: II. High-dose methotrexate (HDM) in acute lymphoblastic leukemia in childhood: A pilot study from April 1981

✍ Moe, Peter Johan ;Wesenberg, Finn ;Kolmannskog, Svein 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

The pilot study using HDM in all cases of ALL in childhood had been run for 4 112 years as of September 1985. Fourteen (23%) of all 62 diagnosed cases of ALL had WBC above 50 x 109/L, all 14 achieved CR. Three of them were below one year of age, two also had WBC above 400 x 109/L, the third infant h

Systemic clearance of methotrexate in th

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

✍ Joseph D. Borsi; Peter Johan Moe 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

The prognostic value of systemic clearance of methotrexate (MTX) has been evaluated in 58 children with acute lymphoblastic leukemia, receiving altogether 380 MTX infusions in a dose range of 0.5 to 33.6 g/mZ. The linear regression analysis of dose-steady state concentration relationship revealed th

Randomized comparison of moderate-dose m

Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study

✍ Lange, Beverly J.; Blatt, Julie; Sather, Harland N.; Meadows, Anna T. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Methotrexate (MTX) infusions of 500-1,000 mg/m2 over 24 hours may improve survival and prevent relapse in children with acute lymphoblastic leukemia (ALL). Childrens Cancer Group (CCG) Study 139 compared weekly oral methotrexate 20 mg/m2/ week (oral MTX) to MTX 500 mg/m2 infused over 24 hours (IV MT

The use of intermediate dose methotrexat

The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia a comparison of three versus six courses

✍ Daniel M. Green; Martin L. Brecher; Leslie E. Blumenson; Mauro Grossi; Arnold I. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 523 KB

A comparative study on the pharmacokinet

A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia

✍ Joseph D. Borsi; Peter Johan Moe 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB